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Abstract
Objective: Increased levels of depressive symptoms, fatigue or pain (all dimensions 
of reduced health-related quality of life (HRQOL)) are common in people with type 2 
diabetes mellitus (DM). Earlier studies have reported associations between low vitamin 
D status and fatigue and depressive symptoms. The aim of the present study was to 
examine the effects of vitamin D supplementation on dimensions of HRQOL in people 
with type 2 DM.
Design: Randomised, double-blind, placebo-controlled trial.
Methods: The effect of monthly cholecalciferol 50,000 IU vs placebo on HRQOL was 
assessed in 275 adults with type 2 DM derived from general practices. HRQOL at baseline 
and after six months using the Short Form 36 Health Survey (SF-36) was collected. Linear 
regression analyses were used to compare the change in HRQOL over time between the 
vitamin D and placebo group.
Results: 187/275 (68%) completed baseline and follow-up SF-36 and were included in 
the analysis. Median serum 25-hydroxyvitamin D almost doubled in the intervention 
group compared to that in the placebo group (58.5–106.0 nmol/L vs 60.0–61.5 nmol/L, 
respectively). A small significant difference (adjusted B: −8.90; 95% CI: −17.16 to −0.65) 
between both groups was seen concerning the SF-36 domain role limitations due to 
physical problems in disadvantage of the vitamin D group.
Conclusions: Six months of vitamin D supplementation did not improve HRQOL in non-
vitamin D-deficient people with type 2 DM managed on oral antidiabetic therapy.
Introduction
With a total number of 415 million people in 2015, 
expecting to increase to a number of 642 million people 
in 2040, diabetes mellitus (DM) is a growing worldwide 
epidemic. It is common knowledge that people with DM 
are at increased risk for microvascular and macrovascular 
complications, including neuropathy, nephropathy, 
retinopathy, peripheral artery disease and cardiovascular 
disease (1). Furthermore, in people with type 2 diabetes 
mellitus (type 2 DM), relatively high prevalences of 
depression, fatigue and (neuropathic) pain were found 
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resulting in a decreased quality of life (2, 3, 4, 5, 6). 
Depressive symptoms and fatigue in people with diabetes 
are related to an increased risk of developing diabetes-
specific complications (2, 3). Moreover, people with 
depressive symptoms and diabetes had an almost 50% 
increased all-cause mortality rate, probably due to non-
optimal self-care (2).
Low vitamin D status is common in people with type 2 
DM (7), and previous observational studies demonstrated 
an association between low vitamin D status and a 
reduced health-related quality of life (HRQOL), fatigue 
and depressive symptoms (8, 9, 10, 11, 12, 13, 14). Two 
recent meta-analyses (15, 16) based on the results of 
randomised controlled trials, which investigated the effect 
of vitamin D supplementation on depressive symptoms, 
suggest an improvement of depressive symptoms after 
vitamin D supplementation (15, 16). Intervention studies 
concerning the effect of vitamin D supplementation 
on fatigue are scarce, and the studies that have been 
executed are difficult to compare as their research designs 
are very different. Lima and coworkers (17) performed a 
randomised placebo-controlled trial in adolescents and 
young adults with juvenile systemic lupus erythematosus 
and found a significant reduction of ‘fatigue-related to 
social life’ score (when using the Kids Fatigue Severity 
Scale) in the vitamin D group compared to placebo after 
24 weeks of oral cholecalciferol 50,000 IU per week (17). 
In addition, a significant improvement in fatigue score 
in all five scales (general, physical, emotional, mental 
and vigour) of the Multidimensional Fatigue Symptom 
Inventory Short Form was seen in primary care people 
with a low vitamin D status and fatigue as their main 
problem, after five weeks of vitamin D supplementation 
(oral ergocalciferol 50,000 IU three times per week) 
(18). However, this study was not blinded or placebo-
controlled. It should be noted that the majority of the 
people included in these studies did not have type 2 DM.
The biological mechanisms linking vitamin D status 
to HRQOL, depressive symptoms and fatigue in people 
with type 2 DM are not clear. Hypothetically, vitamin D 
deficiency may contribute to poor glycaemic control (19), 
which in turn leads to a higher risk to develop microvascular 
and macrovascular complications in the long term 
(19). Furthermore, due to the immunomodulatory 
properties of vitamin D and its association with oxidative 
stress, vitamin D may influence low-grade systemic 
inflammation, which is linked to both depressive 
symptoms and insulin resistance (20, 21). Another 
possible link between vitamin D status and depressive 
symptoms is an elevated parathyroid hormone (PTH) 
level that has been linked to depressive symptoms and 
insulin resistance and is increased in the state of vitamin 
D deficiency (22, 23). Moreover, vitamin D itself seems to 
have cardioprotective effects as well (24). Based on these 
findings, we hypothesise a positive effect of vitamin D 
supplementation on fatigue and depressive symptoms 
in people with type 2 DM. The aim of this study was to 
test whether six months of vitamin D supplementation 
improves the Short Form 36 (SF-36) Health Survey domain 
scores, especially the domains’ physical functioning, role 
limitations due to physical problems, social functioning, 
role limitations due to emotional problems, mental 
health and vitality, in people with type 2 DM, using a 
randomised double-blind placebo-controlled trial design.
Subjects and methods
Study design and patients
The SUNNY trial (acronym for StUdy the effect of 
vitamiN  D supplemeNtation on glYcaemic control 
in type  2 DM) is a double-blind randomised placebo-
controlled clinical trial, with the primary aim to determine 
the effect of vitamin D supplementation on glycaemic 
control in people with type 2 DM (25). Secondary aim 
was to investigate whether vitamin D supplementation 
improved the dimensions of HRQOL (25). The trial was 
conducted in five general practices in and around the 
city of Alkmaar, the Netherlands, latitude 52°, between 
July 2012 and April 2013. Adult persons (≥18  years) 
with type 2 DM treated with lifestyle advice, metformin, 
and/or sulfonylurea derivatives (SU derivatives) were 
invited for participation in the study. Serum HbA1c had 
to be stable and below or equal to 8.0% (64 mmol/mol) 
for the last three months without recent changes in 
hypoglycaemic agents. Main exclusion criteria were an 
impaired renal function (estimated glomerular filtration 
rate (eGFR) <30 mL/min calculated from serum creatinine 
using the MDRD formula), any granuloma forming 
disorder, hypercalcaemia (serum calcium >2.65 nmol/L) 
of any reason, serum 25-hydroxyvitamin D (25(OH)
D) <15 nmol/L or >150 nmol/L, urolithiasis, psychiatric 
treatment for schizophrenia, organic mental disorder 
or bipolar disorder currently or in the past, insufficient 
knowledge of the Dutch language and substance abuse 
(other than nicotine) or no signed informed consent. 
Withdrawal criteria for premature termination of the 
trial were increase of HbA1c 69 mmol/mol (>8.5%), 
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hypersensitivity to cholecalciferol or placebo, onset of 
urolithiasis, any change in antidiabetic medication or 
serum 25(OH)D <15 or >250 nmol/L, and during the study, 
people were not allowed to take vitamin D supplements.
This trial protocol was approved by the Medical 
Ethics Committee of Noord-Holland, the Netherlands 
and was conducted according to the principles of the 
Declaration of Helsinki (NTR3154). A detailed description 
of the protocol can be found elsewhere (25). Consent 
of all participants was obtained after full explanation of 
the purposes and nature of all procedures used in the 
SUNNY trial.
Intervention
All participants were randomised according to either an 
oral dose of cholecalciferol 50,000 IU or an identically 
looking placebo once a month for 6  months (Meander 
Medical Center, Amersfoort, the Netherlands).
Outcome measures
Change in HRQOL after six months of vitamin D 
supplementation was one of the secondary outcomes 
described in the study protocol of the SUNNY trial (25). 
HRQOL was assessed at baseline and six months after 
baseline, using the Dutch version of the Short Form 36 
(SF-36) Health Survey, which was translated and validated 
by Aaronson and coworkers in 1994 (26). The SF-36 
questionnaire is composed of 36 questions and represents 
eight domains and two summary measures: physical 
functioning, role limitations due to physical problems, 
bodily pain, general health perceptions (together 
presenting the physical component summary), mental 
health, vitality, social functioning and role limitations 
due to emotional problems (together presenting the 
mental component summary). For each domain, scores 
are summed and converted to a scale from 0 to 100, with 
lower scores indicating a poorer HRQOL (27).
Demographic data, medical history, the use of 
vitamin D supplements and diabetes-specific elements 
(treatment, complications and duration) were collected 
from medical records and during interviews. Lifestyle 
information including smoking status (yes/no), alcohol 
use (units per week), sun exposure (hours per week) and 
physical activity (hours per week) were self-reported and 
gathered through interviews. Standard anthropometric 
data (height and weight) and venous blood collection 
were obtained from each person. Serum 25(OH)D was 
measured using an iSYS automated immunoanalyzer 
(IDS GmbH, Frankfurt, Germany). Data were collected at 
baseline and after six months.
Randomisation
The participants were randomised 1:1 according to the 
method of block randomisation with a block size of 10. 
No stratification was used. The randomisation procedure 
was performed by the pharmacist. The participants and 
the research team remained blinded until the end of 
the study.
Statistical analysis
People who completed the study (returned questionnaires 
at baseline and 6 months) were included in the statistical 
analyses. In case of one or two missing SF-36 domains, 
linear imputation was used. When more SF-36 domains 
were missing, the people were excluded. All data were 
analysed using the Statistical Package of the Social 
Sciences (SPSS software, version 20.0; SPSS Inc.). Baseline 
characteristics were presented as means ± s.d., frequencies 
(%) or as median (interquartile range (IQR)) in case of a 
skewed distribution.
Linear regression analysis was used to assess the 
mean difference between intervention and placebo 
group after six months (mean difference reported as B 
and β). Change in SF-36 domain score was analysed as 
a dependent outcome with randomisation group as an 
explanatory variable. To correct for regression to the 
mean, all analyses were adjusted for its baseline value. In 
case of skewed distribution, the separate SF-36 domains 
were log transformed.
As we know that men and women provide different 
outcome on the SF-36 questionnaire and oestrogen 
use may increase the concentration of the vitamin 
D-binding protein and improve hydroxylation of 
vitamin D in the liver, the models will be tested for effect 
modification by gender (26). Furthermore, all analyses 
were corrected for confounding variables, which were 
selected based on literature, including age, gender (if no 
effect modification), BMI and season of blood collection. 
Subgroup analyses were performed in people with low 
vitamin D status, defined as 25(OH)D <50 nmol/L 
according to the practical guidelines of the Endocrine 
Society and the Institute of Medicine.
A two-sided P value of <0.05 was considered as 
significant.
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Results
A total number of 787 people were screened for 
eligibility of which 300 persons were recruited and 
finally 275 persons (no show: n = 25) were randomised 
to either vitamin D supplementation (n = 136) or 
placebo (n = 139) (Fig.  1). 487 (62%) people were 
excluded from the study because they did not meet 
the inclusion criteria (75%, mostly because they used 
insulin) or refused to participate (25%). During the trial, 
17 people met the withdrawal criteria for premature 
termination due to change in antidiabetic medication 
(n = 10), HbA1c >69 mmol/mol (>8.5%) (n = 5) or serum 
25(OH)D <15 or >250 nmol/L (n = 2) and nine people 
were lost to follow-up. SF-36 response rate at baseline 
was 88% (241/275) and 89% at six months of follow-up 
(191/215), total SF-36 response rate was 70% (191/275). 
Linear imputation was executed in four people at 
baseline and two people at follow-up for the SF-36 
domains role limitations due to physical problems, 
general health perceptions and role limitations due 
to emotional problems. Four people were excluded 
because information on two or more SF-36 domains 
were missing, resulting in 187/275 (68%) people with 
complete data.
Baseline demographic, clinical characteristics and 
HRQOL of all people included in the vitamin D group 
and in the placebo group are presented in Table 1. Mean 
age was 68 years ± 8 and 67% of the people were men. 
The median diabetes duration was 6 years (3–8) with a 
median HbA1c of 51 (46–54 mmol/mol) (6.8 (6.4–7.1%)). 
Overall mean serum 25(OH)D was 61.1 ± 22.6 nmol/L. 
At baseline, 63 people (34%) had a serum 25(OH)D level 
of 50 nmol/L or less; a serum 25(OH)D level between 50 
and 75 nmol/L was present in 79 people (42%) and 45 
people (24%) had a serum 25(OH)D >75 nmol/L. After 
six months of vitamin D supplementation, the median 
25(OH)D level almost doubled in the vitamin D group 
from 58.5 (43.0–75.0) to 106.0 (85.0–117.0) nmol/L, 
whereas in the placebo group, the 25(OH)D level 
remained stable (serum 25(OH)D: 60.0 (44.0–74.0) to 
61.5 (37.0–85.5) nmol/L). In the intervention group, 
73% of the people achieved a serum 25(OH)D level 
≥75 nmol/L at three months, and 84% after six months 
of vitamin D supplementation. No differences in baseline 
characteristics were seen between the people who were 
randomised (n = 275) and those finally analysed (n = 187) 
(data not shown).
Serum 25(OH)D and HRQOL
The present study revealed that vitamin D supplementation 
did not affect HRQOL (Fig. 2 and Table 2) in people with 
type 2 DM. No effect modification by gender was seen 
(data not shown). A small significant difference, to the 
detriment of the vitamin D group, was observed in the 
SF-36 domain role limitations due to physical problems 
(adjusted B: −8.90; 95% CI: −17.16 to −0.65).
In the group people with 25(OH)D <50 nmol/L (34%), 
mean age was 67 years ± 8, 56% of the people were men 
and mean serum 25(OH)D was 38 ± 8 nmol/L. Linear 
regression revealed no differences in HRQOL between 
the vitamin D and placebo group in this pre-specified 
subgroup analysis (data not shown).
14 discontinued!†
   4 lost to follow-up 
   10 met criteria premature termination 
15 did not return second SF-36 
Screened (n = 787) 
Randomised  (n = 275) 
Excluded (n = 487) 
    Did not meet inclusion criteria* (n = 364) 
    Declined to participate (n = 123) 
No show after recruitment (n = 25) 
95/104 (91%) returned second SF-36 
93 analysed
Placebo group (n = 139) Vitamin D group (n = 136) 
116/139 (84%) returned first (baseline) SF-36  125/136 (92%) returned first (baseline) SF-36 
23 did not return baseline SF-36 
12 discontinued!†
   5 lost to follow-up 
   7 met criteria premature termination 
9 did not return second SF-36 
11 did not return baseline SF-36
96/111 (87%) returned second SF-36 
Figure 1
Participant flowchart. *Most people did not meet 
the inclusion criteria because of insulin therapy. 
†Did not received second SF-36. ‡2 people 
excluded from analyses because ≥2 SF-36 
domains were missing at baseline or follow-up.
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Table 1 Baseline demographic and clinical characteristics in the vitamin D group and the placebo group (n = 187).
Vitamin D group (n = 94) Placebo group (n = 93)
Demographic parameters
Age (years) 67 ± 8 68 ± 9
Male 68 (72) 57 (61)
Diabetes duration (years) 6 (3–8) 6 (4–8)
White skin colour 91 (95) 90 (95)
Antidiabetic treatment
 Lifestyle adjustments 3 (3) 6 (7)
 Metformin 66 (70) 48 (52)
 SU derivatives 2 (2) 5 (5)
 Metformin and SU derivatives 23 (25) 34 (37)
Microvascular complications* ≥1 25 (27) 13 (14)
Cardiovascular disease, yes 28 (30) 33 (36)
Single 8 (9) 20 (22)
Education level
 Low 63 (69) 64 (72)
 Middle 21 (23) 18 (20)
 High 7 (8) 8 (9)
Employment status
 Paid employment 24 (26) 25 (26)
 Unemployed or incapacitated 8 (9) 7 (8)
 Retired 62 (66) 61 (66)
Alcohol use >2 units/day 12 (13) 12 (13)
Current smoker 15 (16) 13 (14)
Use of vitamin D supplements† 14 (15) 9 (10)
Physical activity
 <2 h/week 31 (33) 22 (24)
 2–5 h/week 40 (43) 52 (56)
 >5 h/week 23 (25) 19 (20)
Sun exposure (%)
 <5 h/week 34 (36) 37 (40)
 5–10 h/week 46 (49) 44 (47)
 >10 h/week 14 (15) 12 (13)
Season of blood collection
 Spring 12 (13) 8 (9)
 Summer 23 (25) 20 (22)
 Autumn 43 (46) 49 (53)
 Winter 16 (17) 16 (17)
Clinical characteristics
BMI (kg/m2) 27.7 (26.0–31.2) 27.5 (25.3–30.6)
HbA1c (mmol/mol) 51 (46–55) 51 (46–53)
HbA1c (%) 6.8 (6.4–7.2) 6.8 (6.4–7.0)
Serum 25(OH)D (nmol/L) 59.0 (43.0–75.0) 60.0 (44.0–74.0)
Serum PTH (pmol/L) 5.1 (3.8–6.8) 5.2 (4.0–6.5)
Health-related quality of life
Physical functioning 85 (70–95) 85 (65–95)
Role limitations physical 100 (50–100) 100 (50–100)
Bodily pain 74 (52–100) 74 (62–100)
General health perceptions 67 (47–77) 62 (47–72)
Mental health 88 (76–92) 80 (64–92)
Role limitations emotional 100 (100–100) 100 (100–100)
Vitality 75 (60–85) 70 (55–85)
Social functioning 100 (88–100) 100 (75–100)
Physical component summary 80 (60–91) 76 (63–87)
Mental component summary 87 (74–91) 82 (70–90)
Continuous variables are presented in mean ± s.d. or median (IQR) depending on normality. Categorical variables are presented in numbers (%).
*Including retinopathy, nephropathy and neuropathy. †Maximum dose of 400 IU vitamin D supplement daily before the start of the trial.
25(OH)D, 25 hydroxyvitamin D; PTH, parathyroid hormone; SU derivatives, sulphonylurea derivatives.
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Discussion
In this randomised, double-blind, placebo-controlled trial 
in Dutch people with well-controlled type 2 DM treated in 
general practice, we found a statistically significant 
decline (B: −8.90; 95% CI: −17.16 to −0.65) in the SF-36 
domain ‘role limitations due to physical problems’ after 
six months of vitamin D supplementation. However, 
concerning the remaining SF-36 domains, no effect of 
vitamin D supplementation was found.
Before interpreting the results of our study, it should 
be emphasised that the SF-36 domain scores were not 
standardised, and they are calculated from different 
numbers of questions with different types of set response 
0 
20 
40 
60 
80 
100 
Physical 
functioning 
Role limitations 
physical 
Bodily pain 
Social functioning 
Mental health 
Role limitations 
emotional 
Vitality 
General health 
perceptions 
Baseline  After 6 months of vitamin D supplementation 
Vitamin D group (n = 94) A
0 
20 
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100 
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Role limitations 
physical 
Bodily pain 
Social 
functioning 
Mental health 
Role limitations 
emotional 
Vitality 
General health 
perceptions 
Baseline  After 6 months of vitamin D supplementation 
Placebo group (n = 93) B
Figure 2
Health-related quality of life domains (SF-36) in 
the vitamin D group (A) and placebo group (B); 
baseline vs after six months of vitamin D 
supplementation (n = 187).
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choices resulting in a fixed value per question, which 
is domain specific. Considering the SF-36 domain role 
limitations due to physical problems, which represent 
only four yes or no questions, thus valuing every question 
with twenty-five points, we interpret the statistically 
significant finding with a beta of only 0.138 (B: −8.90; 
95% CI: −17.16 to −0.65) as clinically not relevant (27).
Other studies exploring the effect of vitamin D on 
HRQOL in people with diabetes are scarce. A recent 
systematic review from Hoffmann and coworkers (28), 
categorised fifteen articles (of which seven randomised 
placebo-controlled trials), which examined the effect 
of vitamin D supplementation on HRQOL according to 
length of intervention (more or less than six months) 
and study population (healthy vs diseased people; no 
studies focusing on diabetes were included). In contrast 
to our results, in four of the seven studies, which were 
derived from the group with diseased people and vitamin 
D intervention for six months or less, an improvement of 
HRQOL (especially in the domains role limitations due 
to physical problems, bodily pain, vitality and physical 
functioning; however, only two studies used (a variation 
of) the SF-36) after vitamin D supplementation was 
found, which was interpreted by the investigators as 
evidence for an small-to-moderate positive effect of 
short-term vitamin D supplementation on HRQOL in 
diseased people (28). However, no meta-analysis could 
be done due to the great heterogeneity in study samples, 
dose and type of vitamin D supplementation and the 
variation of HRQOL instruments that had been used. 
The before-mentioned study results should be viewed 
with caution as the quality of evidence is low due to poor 
methodological quality. Also, many of the differences 
in HRQOL that have been reported were small and not 
likely to be of value in the clinical setting. In addition, 
the only randomised placebo-controlled trial in this 
review with the maximal points for methodology, found 
no effect of vitamin D supplementation (daily oral 800 IU 
vitamin D3) on the physical component summary or 
mental component summary in elderly people >70 years 
with previous low trauma osteoporotic fracture using the 
SF-12 (shortened version of the SF-36) after 24–62 months 
of follow-up (29).
Moreover, one recent double-blind, placebo-
controlled study including 60 people receiving haemo-
dialysis of whom 55% had a history of diabetes, did not 
demonstrate an effect of vitamin D supplementation 
(cholecalciferol 50,000 IU/week for eight weeks followed 
by 50,000 IU/month for four months) on HRQOL (using 
KDQOL-36, a kidney disease-specific measure of HRQOL 
including several parts of the SF-36 questionnaire) after 
six months of follow-up (30).
The main limitation of our study, which could 
explain that we found no positive effect of vitamin D 
supplementation on HRQOL in the present study, is the 
relatively good baseline HRQOL of several SF-36 domains 
in our study population that may have resulted in ceiling 
effects. In addition, the SF-36 domain scores in our study 
population are comparable with the SF-36 domain scores 
in the general Dutch population (26), suggesting low 
disease burden with few mental and physical limitations, 
leaving almost no opportunity for improvement. The low 
disease burden in our study population is also reflected 
in the small number of people with one or more than 
one microvascular complications (n = 38, 20%) and 
the good glycaemic control with a median HbA1c of 51 
(46–54) mmol/mol (6.8 (6.4–7.1%)).
Furthermore, when expecting a positive effect of 
vitamin D supplementation on HRQOL by reducing 
systemic low-grade inflammation or improving glycaemic 
Table 2 Health-related quality of life (SF-36 domains) in the vitamin D group and the placebo group (n = 187).
Δ Vitamin D group (n = 94) Δ Placebo group (n = 93) β* B* 95% CI P
Physical functioning −0.55 ± 12.77 1.21 ± 11.70 −0.062 −1.51 −4.99; 1.96 0.39
Role limitations physical −5.32 ± 32.77 4.84 ± 32.61 −0.138 −8.9 −17.16; −0.65 0.04†
Bodily pain −0.24 ± 19.33 2.40 ± 16.59 −0.07 −2.52 −7.30; 2.27 0.3
General health perceptions 0.37 ± 13.39 3.10 ± 13.61 −0.063 −1.71 −5.44; 2.02 0.37
Mental health −1.68 ± 11.78 −0.12 ± 13.09 −0.033 −0.83 −4.42; 2.77 0.65
Role limitations emotional −3.72 ± 34.92 1.08 ± 33.50 −0.063 −4.31 −13.00; 4.37 0.31
Vitality −2.71 ± 13.35 −1.00 ± 12.17 −0.064 −1.62 −5.11; 1.88 0.36
Social functioning‡ 0.00 (−12.50 to 0.00) 0.00 (−12.50 to 0.00) 0.95 0.95 0.80; 1.11 0.49
Physical component summary −1.50 ± 13.82 2.89 ± 11.39 −0.15 −3.77 −7.26; −0.28 0.04†
Mental component summary‡ 0.79 (−6.38 to 6.00) 0.00 (−4.50 to 7.50) 0.93 0.97 0.91; 1.04 0.34
A positive β value indicates an increase in the SF-36 domain in the vitamin D group compared to the placebo group.
*Adjusted for age, gender, BMI, baseline SF-36 domain, baseline 25-hydroxyvitamin and season of blood collection; †P < 0.05; ‡Using log-transformed 
values; β of 0.95 (social functioning) indicating a 5% lower SF-36 score in the vitamin D group vs the placebo group after six months.
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control leading to reduced or less severe diabetes-specific 
complications, the relatively short duration of the trial 
could be another reason for not finding an improvement 
of HRQOL after vitamin D supplementation.
Last, with a median 25(OH)D level of 58.5 nmol/L 
(43.0–75.0) in the vitamin D group at baseline, our 
subjects are already replete in vitamin D according to 
the current guidelines of the Institute of Medicine from 
2011, which defines vitamin D deficiency as 25(OH)D 
<50 nmol/L in respect to bone health. However, 
Spedding and coworkers (31) suggested different 25(OH)
D levels required for non-skeletal diseases and reported 
a minimum 25(OH)D level of 75 nmol/L for reducing 
depressive symptoms (level II evidence: randomised 
controlled trial) (31). With a median 25(OH)D level of 
106.0 (85.0–117.0) in the vitamin D group at the end 
of the study, vitamin D intervention was effective to 
increase 25(OH)D concentration to a level of which an 
improvement in depressive symptoms could be expected.
The strengths of our study are the randomised, 
double-blind, placebo-controlled design, the use of a well-
validated questionnaire to determine HRQOL and the 
large study population.
In conclusion, six months of vitamin D 
supplementation did not improve HRQOL in people 
with tightly controlled type 2 DM derived from general 
practices. Longitudinal studies in people with poorly 
controlled type 2 DM, with multiple measurements over 
time concerning physical limitations, mental health 
and vitality and factors possible affecting these domains 
including low 25(OH)D level, inflammation factors, 
diabetes-specific treatment and complications and lifestyle 
factors are necessary to understand and eventually affect, 
the relationship between diabetes and a reduced (health-
related) quality of life.
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